PCIA
RANI icon

Prime Capital Investment Advisors’s Rani Therapeutics RANI Stock Holding History

Prime Capital Investment Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.44K Sell
11,485
-15,723
-58% -$20.1K ﹤0.01% 1037
2025
Q4 		$36.7K Hold
27,208
– – ﹤0.01% 1006
2025
Q3 		$13.6K Hold
27,208
– – ﹤0.01% 996
2025
Q2 		$14K Hold
27,208
– – ﹤0.01% 943
2025
Q1 		$34.3K Hold
27,208
– – ﹤0.01% 1035
2024
Q4 		$37.3K Buy
27,208
+15,723
+137% +$33K ﹤0.01% 920
2024
Q3 		$24.8K Sell
11,485
-2,397
-17% -$6.87K ﹤0.01% 911
2024
Q2 		$52.8K Hold
13,882
– – ﹤0.01% 901
2024
Q1 		$43.2K Sell
13,882
-2,800
-17% -$9.63K ﹤0.01% 982
2023
Q4 		$55.4K Hold
16,682
– – ﹤0.01% 936
2023
Q3 		$36.3K Hold
16,682
– – ﹤0.01% 742
2023
Q2 		$68.7K Buy
+16,682
New +$77.4K ﹤0.01% 741
2023
Q1 		– Sell
-33,502
Closed -$198K – 634
2022
Q4 		$198K Buy
+33,502
New +$244K 0.01% 499

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Prime Capital Investment Advisors's RANI Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Rani Therapeutics (RANI) stake by 58% in Q1 2026, selling an estimated $20.1K and leaving 11,485 shares worth $8.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Prime Capital Investment Advisors first reported a position in RANI in Q4 2022 and has held it in 13 quarters since. The position peaked at $198K in Q4 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Prime Capital Investment Advisors held 11,485 shares of Rani Therapeutics worth $8.44K as of Q1 2026.
  • Prime Capital Investment Advisors sold 15,723 Rani Therapeutics shares in Q1 2026, an estimated $20.1K.
  • Rani Therapeutics made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #1037 holding.
  • Prime Capital Investment Advisors first reported a position in Rani Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Prime Capital Investment Advisors's Rani Therapeutics position peaked at $198K in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.